Last reviewed · How we verify
Vagitrol V
Vagitrol V is a medication that works by inhibiting the action of a specific enzyme.
Vagitrol V is a medication that works by inhibiting the action of a specific enzyme. Used for Gastroesophageal reflux disease (GERD), Erosive esophagitis.
At a glance
| Generic name | Vagitrol V |
|---|---|
| Sponsor | Janssen-Cilag, S.A. |
| Drug class | proton pump inhibitor |
| Target | H+/K+ ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of Vagitrol V involves the inhibition of a particular enzyme, which plays a crucial role in the development of the condition it is used to treat. This inhibition leads to a decrease in the symptoms associated with the condition.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Erosive esophagitis
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vagitrol V CI brief — competitive landscape report
- Vagitrol V updates RSS · CI watch RSS
- Janssen-Cilag, S.A. portfolio CI